<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04016662</url>
  </required_header>
  <id_info>
    <org_study_id>AIDE T1D</org_study_id>
    <nct_id>NCT04016662</nct_id>
  </id_info>
  <brief_title>Automated Insulin Delivery in Elderly With Type 1 Diabetes (AIDE T1D)</brief_title>
  <acronym>AIDE T1D</acronym>
  <official_title>A Randomized Cross-over Trial Evaluating Automated Insulin Delivery Technologies on Hypoglycemia and Quality of Life in Elderly Adults With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jaeb Center for Health Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>DexCom, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tandem Diabetes Care, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Minnesota - Advanced Research and Diagnostic Laboratory</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AdventHealth Diabetes Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Washington State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jaeb Center for Health Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-center, randomized, crossover trial consisting of three sequential 12-week periods,
      with the HCL feature used during one period, the PLGS feature used during one period and SAP
      therapy (control) during one period. The crossover trial will be preceded by a run-in phase
      in which participants will receive training using the study devices (Dexcom G6 and Tandem
      t:slim X2 pump). After the last crossover period, participants will be given the opportunity
      to use study devices for an additional 12 weeks to assess preference of system use (PLGS, HCL
      or SAP) and associated characteristics, durability and safety in a more real-world setting
      with less frequent study contact.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Automated insulin delivery (AID) technologies hold the promise of optimizing glycemic control
      and reducing the burden of diabetes care for patients with Type 1 Diabetes (T1D). However,
      clinical trials of lower burden AID technologies have not included older adults in sufficient
      numbers to allow for focused evaluation of efficacy and quality of life (QOL) impacts that
      may differ from those observed in younger age groups. Most notably, primary endpoints have
      focused on reducing hyperglycemia, while avoidance of hypoglycemia is of upmost concern for
      older adults with T1D. T1D Exchange clinic registry data have shown severe hypoglycemia (SH)
      occurs more commonly in older adults with longstanding T1D than in younger individuals with
      events occurring just as often with HbA1c levels &gt;8.0% as with HbA1c levels &lt;7.0%. These data
      do not support the strategy of &quot;raising the HbA1c&quot; as being an effective approach for
      hypoglycemia prevention in older adults with T1D. In addition to acutely altered mental
      status, hypoglycemia is associated with an increased risk for falls leading to fractures, car
      accidents, emergency room (ER) visits, hospitalizations, and mortality resulting in
      substantial societal costs. The occurrence of hypoglycemia, hypoglycemia unawareness and fear
      of hypoglycemia have adverse effects on overall QOL of both individuals with T1D and their
      families.

      While continuous glucose monitoring (CGM) technology alone has the potential to be beneficial
      in reducing hypoglycemia in older patients, our preliminary data from the Wireless
      Innovations for Seniors with Diabetes Mellitus (WISDM) trial shows a majority of patients
      still have frequent hypoglycemia even when using CGM. Thus, knowledge of CGM alone may not be
      sufficient to avoid hypoglycemia in this population. Predictive low-glucose suspend
      algorithms have particular promise when the primary goal is hypoglycemia avoidance rather
      than glucose reduction. Whether the added complexity of closed loop systems provides
      additional glycemic benefit is not known. There is a critical need to determine whether
      automated insulin delivery can reduce hypoglycemia in the older adult population with T1D.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Randomized crossover trial with three 12-week crossover periods (HCL during one period, PLGS during one period, and SAP therapy (control) during one period) preceded by a run-in phase.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CGM Measured Time &lt;70 mg/dL</measure>
    <time_frame>12 weeks for each arm of the crossover</time_frame>
    <description>Percentage of sensor glucose values &lt;70 mg/dL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemia</measure>
    <time_frame>12 weeks for each arm of the crossover</time_frame>
    <description>Percentage of sensor glucose values &lt;54 mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemia</measure>
    <time_frame>12 weeks for each arm of the crossover</time_frame>
    <description>Frequency of CGM-measured hypoglycemic events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose Control</measure>
    <time_frame>12 weeks for each arm of the crossover</time_frame>
    <description>Mean glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose Control</measure>
    <time_frame>12 weeks for each arm of the crossover</time_frame>
    <description>Percentage of sensor glucose values 70 to 180 mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose Control</measure>
    <time_frame>12 weeks for each arm of the crossover</time_frame>
    <description>Coefficient of variation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hyperglycemia</measure>
    <time_frame>12 weeks for each arm of the crossover</time_frame>
    <description>Percentage of values &gt;180 mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hyperglycemia</measure>
    <time_frame>12 weeks for each arm of the crossover</time_frame>
    <description>Percentage of values &gt;250 mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>12 weeks for each arm of the crossover</time_frame>
    <description>HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemia Unawareness</measure>
    <time_frame>12 weeks for each arm of the crossover</time_frame>
    <description>Gold survey</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Patient Reported Questionnaires</measure>
    <time_frame>12 weeks for each arm of the crossover</time_frame>
    <description>Hypoglycemia Fear Survey</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Reported Questionnaires</measure>
    <time_frame>12 weeks for each arm of the crossover</time_frame>
    <description>Hypoglycemia Confidence</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Reported Questionnaires</measure>
    <time_frame>12 weeks for each arm of the crossover</time_frame>
    <description>Diabetes Distress Scale. 6-point scale from not a problem to a very serious problem. A high total DD score may indicate overall severity.</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Reported Questionnaires</measure>
    <time_frame>12 weeks for each arm of the crossover</time_frame>
    <description>AIDE Technology Acceptance is based on the Technology Acceptance Model. 5-point scale from strongly disagree to strongly agree. A high score may indicate acceptance of technology.</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Reported Questionnaires</measure>
    <time_frame>12 weeks for each arm of the crossover</time_frame>
    <description>System Usability. 5-point scale from strongly disagree to strongly agree. A high score may indicate ease of system usability.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Hybrid Closed Loop Control (HCL)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The HCL intervention arm will utilize the Tandom t:slim X2 with Control-IQ Technology and Dexcom G6 CGM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Predictive Low-Glucose Insulin Suspension (PLGS)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The PLGS intervention arm will utilize the Tandom t:slim X2 with Basal-IQ Technology and Dexcom G6 CGM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sensor-Augmented Pump (SAP)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The SAP arm will utilize the Tandem t:slim X2 without HCL or PLGS features turned on and Dexcom G6 CGM</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tandom t:slim X2 with HCL or PLGS</intervention_name>
    <description>The system components include the t:slim X2 with Control-IQ Technology and the Dexcom CGM G6. The modular control algorithm has a safety supervision module that limits insulin delivery to prevent hypoglycemia at all times. The algorithm gradually decreases hyperglycemia from bedtime to reach a target of 120 mg/dL by waking time. During awake hours, the control algorithm attempts to maintain glucose within a target range (112.5 to 160 mg/dL) with meal time insulin boluses delivered based on usual bolus procedures undertaken by patients on an insulin pump (Hybrid closed loop).
The system components include the t:slim X2 with with Basal-IQ Technology and the Dexcom CGM G6. The PLGS System is able to stop and resume basal insulin delivery automatically in response to predicted or low sensor glucose values, thereby reducing the incidence and duration of hypoglycemic episodes. The pump includes the hypoglycemia minimization strategy that will issue insulin delivery commands.</description>
    <arm_group_label>Hybrid Closed Loop Control (HCL)</arm_group_label>
    <arm_group_label>Predictive Low-Glucose Insulin Suspension (PLGS)</arm_group_label>
    <other_name>Tandom t:slim X2 with Control-IQ Technology</other_name>
    <other_name>Tandom t:slim X2 with Basal-IQ Technology</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Clinical diagnosis of type 1 diabetes

          2. Age â‰¥ 65 years old

          3. T1D Duration of at least 1 year

          4. HbA1c &lt; 10.0% from point of care or local lab at time of screening visit

          5. Insulin regimen involves basal/bolus insulin via insulin pump or multiple daily
             injections

          6. Willingness to use a rapid acting insulin compatible with the Tandem t:slim X2 pump
             (currently aspart and lispro; other rapid acting insulins likely to be approved for
             pump use prior to study initiation such as Fiasp)

          7. Familiarity with and willingness to use a carbohydrate ratio for meal boluses

          8. Willing to use study devices and automated insulin delivery features

          9. Participant is independently managing his/her diabetes with respect to insulin
             administration and glucose monitoring (may include assistance from spouse or other
             caregiver)

         10. Participant understands the study protocol, agrees to comply with it and is able to
             successfully pass the consent understanding assessment with no more than 2 attempts

         11. Participant comprehends written and spoken English

         12. At least 240 hours of CGM readings available during the end of run-in assessment

         13. At least 2% of time with CGM glucose levels &lt; 70 mg/dL prior to SAP initiation

        Exclusion Criteria:

          1. Use of PLGS technology or HCL insulin delivery in in the past 3 months

          2. Clinical diagnosis by a primary care provider, neurologist or psychiatrist of
             dementia, in the investigator's opinion a suspected severe cognitive impairment such
             that it would preclude ability to understand the study or use devices, or a score of
             13 or less on the Montreal Cognitive Assessment (mild cognitive impairment is not an
             exclusion)

          3. Severe vision impairment that would prohibit use of the devices

          4. A condition, which in the opinion of the investigator or designee, would put the
             participant or study at risk, including any contraindication to the use of any of the
             study devices per FDA labeling

          5. Known adhesive allergy or skin reaction during the run-in pre-randomization phase or
             previous difficulty with pump and CGM insertions that would preclude participation in
             the randomized trial

          6. Concurrent use of any non-insulin glucose-lowering agent other than metformin
             (including GLP-1 agonists, Symlin, DPP-4 inhibitors, SGLT-2 inhibitors, sulfonylureas)

          7. Stage 4 or 5 renal disease

          8. The presence of a significant medical or psychiatric condition or use of a medication
             that in the judgment of the investigator may affect completion of any aspect of the
             protocol, or is likely to be associated with life expectancy of &lt;1 year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kellee Miller, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jaeb Center for Health Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alandra Verdejo, MPH</last_name>
    <phone>8139758690</phone>
    <email>averdejo@jaeb.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kellee Miller</last_name>
    <phone>8139758690</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AdventHealth Diabetes Institute</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>July 9, 2019</study_first_submitted>
  <study_first_submitted_qc>July 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2019</study_first_posted>
  <last_update_submitted>April 22, 2020</last_update_submitted>
  <last_update_submitted_qc>April 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

